|
1
|
Tamayo M, Martín-Nunes L, Piedras MJ, Martin-Calvo M, Martí-Morente D, Gil-Fernández M, Gómez-Hurtado N, Moro MÁ, Bosca L, Fernández-Velasco M, Delgado C. The Aryl Hydrocarbon Receptor Ligand FICZ Improves Left Ventricular Remodeling and Cardiac Function at the Onset of Pressure Overload-Induced Heart Failure in Mice. Int J Mol Sci 2022; 23:ijms23105403. [PMID: 35628213 PMCID: PMC9141655 DOI: 10.3390/ijms23105403] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2022] [Revised: 05/06/2022] [Accepted: 05/10/2022] [Indexed: 02/07/2023] Open
Abstract
Adverse ventricular remodeling is the heart's response to damaging stimuli and is linked to heart failure and poor prognosis. Formyl-indolo [3,2-b] carbazole (FICZ) is an endogenous ligand for the aryl hydrocarbon receptor (AhR), through which it exerts pleiotropic effects including protection against inflammation, fibrosis, and oxidative stress. We evaluated the effect of AhR activation by FICZ on the adverse ventricular remodeling that occurs in the early phase of pressure overload in the murine heart induced by transverse aortic constriction (TAC). Cardiac structure and function were evaluated by cardiac magnetic resonance imaging (CMRI) before and 3 days after Sham or TAC surgery in mice treated with FICZ or with vehicle, and cardiac tissue was used for biochemical studies. CMRI analysis revealed that FICZ improved cardiac function and attenuated cardiac hypertrophy. These beneficial effects involved the inhibition of the hypertrophic calcineurin/NFAT pathway, transcriptional reduction in pro-fibrotic genes, and antioxidant effects mediated by the NRF2/NQO1 pathway. Overall, our findings provide new insight into the role of cardiac AhR signaling in the injured heart.
Collapse
Affiliation(s)
- María Tamayo
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
| | - Laura Martín-Nunes
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
| | - María José Piedras
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
- Facultad de Medicina, Universidad Francisco de Vitoria (UFV), 28223 Madrid, Spain
| | - María Martin-Calvo
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
| | - Daniel Martí-Morente
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
| | - Marta Gil-Fernández
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
- Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain
| | - Nieves Gómez-Hurtado
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
| | - María Ángeles Moro
- Centro Nacional de Investigaciones Cardiovasculares (CNIC), Melchor Fernández Almagro 3, 28029 Madrid, Spain;
| | - Lisardo Bosca
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
| | - María Fernández-Velasco
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
- Innate Immune Response Group, IdiPAZ, La Paz University Hospital, 28046 Madrid, Spain
| | - Carmen Delgado
- Instituto de Investigaciones Biomédicas “Alberto Sols” (CSIC-UAM), CIBER de Enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain; (M.T.); (L.M.-N.); (M.J.P.); (M.M.-C.); (D.M.-M.); (M.G.-F.); (N.G.-H.); (L.B.); (M.F.-V.)
- Correspondence:
| |
Collapse
|